The anticipated growth is mainly driven by ten new pipeline drugs expected to be introduced to the market by 2034.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...

Skin manifestations are common in patients with SLE. A recent study reported increased site-specific recurrence of cutaneous lupus erythematosus (CLE).1 While this study included a proportion of ...

Data suggest incidence and prevalence of systemic lupus erythematosus (SLE) vary widely among regions, although the authors noted some regions have been studied more extensively than others. A new ...

As The European Lupus Society’s 15th annual soiree approaches, the Clinical Trials Arena team takes a look at four promising therapies in the SLE pipeline.

Please provide your email address to receive an email when new articles are posted on . “Due to early meticulous diagnosis and the progress of treatment, survival rates for SLE patients have increased ...

The research shows a disease-specific quality-of-life (QOL) tool is more sensitive than a generic version. A new study shows different medications for systemic lupus erythematosus (SLE) have different ...

Discrimination was linked to increased systemic lupus erythematosus symptom burden, mediated by symptoms of depression and ...

When choosing my home for the next four years, it was Stanford’s distinct — but largely under-advertised — residential program that tipped the scale for me. Like most international Indian applicants, ...